A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
Metadata only so far. Questions are answered only with quotes from this document. Source: ctgov, ctgov, retrieved 2026-11-02.
Stopped early
Record metadata
- Phase
- Phase 1
- Status
- Terminated
- Start
- 2024-10-18
- End
- 2026-01-29
- Enrollment
- 17
- Sites
- 6
- Sponsor class
- INDUSTRY
Not in the data yet: a trial card. Cards (population, design, endpoints, result direction, each tied to a quote) arrive with the knowledge layer’s card lane. The fields above are registry or bibliographic metadata, not quotes.
Ask this document
Answers come only from this document’s licensed passages, as highlighted quotes. If it doesn’t say, you get that instead of a guess.
Source text
No passages are loaded for this document yet.